Immunotherapy of Mad109 murine lung carcinoma in BALB/c mice. Five days after implantation, groups of mice (n = 5) were treated intravenously for 4 consecutive days with 3 different concentrations of (A) chTNT-3/IL-2 WT, (B) chTNT-3/Arg38Trp, or (C) chTNT-3/Asn88Arg fusion proteins. Data are represented as means ± standard deviations.